



Match Maker/ Pharmaceutical Process Innovations/ 20 March 2025



Highly efficient process for the preparation of sitagliptin via rhodium catalyzed asymmetric hydrogenation


Lead Inventor: Dr. Samir Chikkali

Organization: CSIR-NCL

TechEx.in Case Manager: Vedang Pawar (vedang.pawar@ventercenter.co.in)

What is Sitagliptin?

- Sitagliptin is a Small Molecule (C₁₆H₁₅F₆N₅O) used in **Oral** formulations for treating **Type 2 Diabetes Mellitus**.
- Molecule Class: DPP-IV (Dipeptidyl Peptidase IV) Inhibitors or
 Gliptins
- **Gliptins** helps improve glycemic control and reduces hemoglobin Alc (HbAlc) levels.
- Therapeutic Use as monotherapy (Phosphate salt) or add-on therapy with metformin and thiazolidinediones.
- National Pharmaceutical Pricing Authority (NPPA) has fixed current price at ₹8/50mg Sitagliptin Phosphate







Market Opportunities

Global Sitagliptin market was valued at <u>USD 6.6 Billion</u> (2023)

(Source: Cognitive Market Research)

Factors driving the market growth:

- Increasing Production Volumes for premium and generic brands
- Reach Increasing as Prices Reduce
- Current Market Price Rs. 40K -100K /kg
- Oral Administration Advantage
- Global Market Accessibility


Industry:

Basic Compound Patent Expired in July 2022

Innovator: Merck & Co.(JANUVIA®) -

Licensed to Sun Pharma to manufacture and sell under the brand names Istavel and Istamet.

Generic Manufacturers: Dr Reddy's, Glenmark, Sun Pharma, JB Chemicals, Cipla, Torrent, Zydus Cadila, Lupin +15 (>1% market share)



Sitagliptin market is predicted to grow at 34% CAGR

from 2024-2031

Source: Cognitive Market Research

34% Global CAGR 2024-2031

Existing Methods

Direct Asymmetric Reductive Amination Two Methods which have been used:

- Overall yield: 96% 99%
- Catalyst: Rhodium/Ruthenium with multiple acidic additives
- Additional costs due to separate isolation and synthesis of the active catalyst
- Merck & Co. Rhodium catalysis process patents (US 7.468.459 & US 7.495,123)
 are set to expire by May 2025

A. Hasen et al.

CF₃

NNN

[Rh]

Josiphos

F

P(t-Bu)

Fe

Bu JOSIPHOS

B. Steinhuebel et al.

F

Salicylic acid


NH2 O

NH2 O

PAr2
PAr2
PAr2
PAr2
(R)-DM-SEGPHOS

Source

Hansen, K. B.; Hsiao, Y.; Xu, F.; et al. Highly Efficient Asymmetric Synthesis of Sitagliptin. J. Am. Chem. Soc. 2009, 131 (25), 8798–8804. https://doi.org/10.1021/ja902462g.




PROCESS FEATURES

Single-Step Synthesis

Very High Enantiomeric Selectivity (99.8% ee)

In-situ Catalyst Generation of Active form

Fewer Solvent Additives




Sitagliptin

Active Catalyst - Rhodium + Ferrolane

Estimated Cost of Raw Materials: USD ~147 per kg of Product Yield

Work flow



05

Match Maker/Pharmaceutical Process Innovations/ 20 March 2025/ Highly Efficient Sitagliptin Production

Current status

Technology Status:


- Status of the technology TRL 4
- Demonstrated at 5g lab scale

Patent Status:

- Patent Coverage : US, India
- Indian Patent No. 406933
- Priority Date: 11 Dec 2018
- US Patent No. US12202833B2
- PCT Filed: WO2020121321A1

Publications:

Chikkali, S.; Suryawanshi, S. R.; Samant, S. D.; Pawar, S. H. Highly Enantioselective Synthesis of Sitagliptin. Asian J. Org. Chem. 2019, 9 (2), 189–191. 10.1002/ajoc.201900709 - Asian J. Org. Chem 2019.



Selected as Cover Feature in Asian J. Org. Chem.

Value Proposition of NCL Method

- High enantiomeric excess while getting higher yield compared to Merck process (US 7733A1)
- Catalyst Patent protected (Granted in IN, US)
- Process Patent protected (Granted in IN, US)
- Cost effective process economics if scaled up

Who should be interested and why?

Who

Pharmaceutical companies & API Manufacturers who are vertically integrating

Why

This Single-step process for sitagliptin synthesis offers advantages such as

- Higher overall yield,
- Lower costs,
- Reduced waste,
- Simplified purification

Team & Organization





Dr Samir Chikkali

Professor & Chief Scientist (G), National Chemical Laboratory, Pune.

- Leads Research Group : POMCAT (POlymer and OrganoMetallic CATalysis)
- Research Interests:

Catalysis, polymer chemistry, sustainable chemistry.

- Postdoctoral work at University of Amsterdam, University of Konstanz (Alexander von Humboldt Fellow).
- Ph.D. from University of Stuttgart, Germany.
- Associate Editor: Bulletin of Materials Science.
- Reviewer for several high impact journals
- Publications: High-impact journals (e.g., JACS, Angewandte Chemie, Green Chemistry).
- Numerous awards and honors.

Best Scientist Award by CSIR-NCL in the Year 2016-17 and 2022-23

About the Institute

CSIR-NCL is a science and knowledge based research, development and consulting organization. It is internationally known for its excellence in scientific research in chemistry and chemical engineering as well as for its outstanding track record of industrial research involving partnerships with industry from concept to commercialization.

POMCAT Research Group @ CSIR-NCL

Key assets and strengths of the team:

- Well-equipped laboratories facilities with sophisticated analytical instrumentation facilities.
- Strong collaborations with academia, industries, and research organizations.
- A significant number of patents and publications in highly efficient catalysis & Polymer synthesis
- Focus on translational research to address industrial and societal challenges.
- Strong track record of developing scalable technologies for industrial applications



Industry collaborations: POMCAT Research Group



















Next Steps

Possible to scale up with support from industry partners from 5 g scale to pilot scale or continuous flow (as required by industry) and in partnerships with other CSIR labs

Seeking

Licensees for technology and IP on "as is where is" basis

Joint development and sponsored R&D partners or scaling up and advancing the technology













For more information, contact:
Vedang Pawar
vedang.pawar@venturecenter.co.in
+91 9156465146